Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238220 · ClinicalTrials.gov registry record
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
A clinical trial, sponsored by Piedmont Healthcare.
- Completed
- Registry status
- 37
- Enrollment target
NCT05238220 is a clinical trial that has completed, run by Piedmont Healthcare. The registered enrollment target is 37 participants.
The verdict
NCT05238220 has completed, sponsored by Piedmont Healthcare.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.
Interventions
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2022-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238220
The ClinicalTrials.gov registry entry for NCT05238220 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Piedmont Healthcare, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valganciclovir is the first listed.
NCT05238220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238220 about?
NCT05238220 is a clinical study titled "Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients". The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in whic...
What is the current status of trial NCT05238220?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2021-01-04. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT05238220?
The interventions under investigation include: Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT05238220?
This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.